Major histocompatibility complex class I molecule presenting Human papillomavirus type 16 E6 and E7 peptides (HLA-HPV16 E6/E7)

Major histocompatibility complex (MHC) class I molecules presenting Human papillomavirus type 16 (HPV16) E6 and E7 peptides are critical therapeutic targets for the treatment of HPV-associated malignancies. These complexes are formed when the intracellular viral oncoproteins E6 and E7 are processed by the proteasome and loaded onto MHC class I molecules, most commonly the HLA-A*02:01 allele, for presentation on the cell surface. Because E6 and E7 are exclusively viral proteins that drive oncogenesis by inactivating the tumor suppressors p53 and pRb, their MHC-presented peptides serve as highly specific tumor-associated antigens that are absent from healthy tissues. Therapeutic strategies targeting these complexes include T-cell receptor (TCR) engineered T cells, therapeutic vaccines, and bispecific molecules such as Immuno-STATs, all designed to redirect the immune system to recognize and eliminate HPV-positive tumor cells. However, clinical efficacy can be challenged by tumor-mediated immune evasion, including the downregulation of MHC class I expression or defects in the antigen-processing machinery (TAP1/TAP2).

Other names

HLA-A*02:01/HPV16 E6/E7 complexHPV16 E6/E7 peptide-MHC complexHLA-A2-restricted HPV16 E6/E7 peptidesMHC-I/HPV16 E6/E7 complexpMHC complex (HPV16 E6/E7)

T-cell receptor-mediated recognition of the peptide-MHC complex leading to cytotoxic T-cell activation and tumor cell lysis.